最高降幅98%！第五批集採中標結果明細出爐
本文來自：醫藥人那些事
第五批集採報價暫吿一段落，本次共納入62種藥品，在2020年省級平台採購金額高達550億元，創下歷次集採新高。從採購藥品劑型看，注射劑的數量佔一半，涉及金額佔70%，成為本次集採的主力劑型。
就目前報價來看，部分品種降價幅度依然很大，比如在多西他賽注射劑的競標中，有6家國產企業中標，中標順位為恆瑞醫藥（22.6）、正大天晴（29.8）、揚子江藥業（30）、齊魯製藥（54.1）、匯宇製藥（58.4）、奧賽康藥業（68.94），降幅均超過90%，而原研企業賽諾菲（860）出局。多西他賽注射液是國內治療腫瘤的常用藥物之一，在國內被列為銷售額超10億級的大品種。
在紫杉醇注射劑的競標中，有三家國產企業中標，中標順位為揚子江藥業（7.24）、無錫紫杉藥業（68）、四川匯宇製藥（73.8），而原研企業百時美施貴寶（763）出局。公開數據顯示，2019年國內公立醫療機構紫杉醇銷售額超過75億元。
本次集採中，30億大品種奧沙利鉑注射劑(50mg/支)競標4家企業中選，分別為恆瑞（91.8）、齊魯製藥（198）、四川匯宇（236.8）、原研賽諾菲（310.51）。
目前看來，部分原研企業報價依然佛系，而國內企業則有多家傳來集採最新消息，比如注射劑主力企業科倫藥業本次11個集採品種全部中選。
齊魯製藥的13個品種中除了地西他濱、法舒地爾未中外，共有11個品種中標。降幅也保持較高水平，但是從選區的順位來看，齊魯本次可能並不是降價最狠的。
此外，四川匯宇4個品種也全部中選，分別為注射用鹽酸苯達莫司汀、紫杉醇注射劑、多西他賽注射劑、奧沙利鉑注射劑。
根據公開信息顯示，恆瑞3個大品種奧沙利鉑、多西他賽、苯磺順阿曲庫銨注射劑均中標，造影劑碘克沙醇出局。
以下是根據公開信息整理的部分企業報價，僅共業內參考，最終以官方公佈為準。
數據來源：Insight數據庫
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
